Homepage Header R1

Diagnostic support you can count on.

Because we know every woman counts on you.

DIAGNOSTIC SOLUTIONSPROVIDER RESOURCES

Your Dedicated Partner in Women’s Health Diagnostics

For over 20 years, Hologic Women’s Health Diagnostics has championed women and their health by providing essential testing for common cervical, sexual, and vaginal issues.

Message Cloud Icon

Partner in advocacy

As your specialized partner we support you in navigating current policies and guidelines as well as advocate with you for advances in care standards.

Verify Cycle Icon

Optimal experience

We are invested in simplifying testing to provide the best possible experience for you and your patients across the continuum of care.

Test Tube Icon

Essential testing

Our market leading, FDA-approved/FDA-cleared molecular diagnostics and cytology tests ensure you have relevant, accurate, and reliable results to inform your decisions.

Explore Solutions and Strategies

Cervical Cancer Woman

Cervical Cancer Screening

LEARN MORE

Cervical Cancer Screening

  • Studies show 1 in 5 women with cervical cancer were missed by screening withHPV-Alone.1,2*
  • Screening with Pap + HPV (Co-testing) identified 70% 
of the cancers missed by HPV-Alone.3*
  • 95% of cervical cancers were detected by testing with Pap + HPV together (Co-testing).1,2
LEARN MORE
Vaginitis Woman

Vaginitis

LEARN MORE

Vaginitis

  • Vaginitis is a leading reason for OBGYN visits.4-6
  • Overlapping symptoms and mixed-infections make clinical diagnosis a challenge.7
  • Traditional methodologies lack detection accuracy, further complicating diagnosis.8
LEARN MORE
Trichomaonas Woman

Sexually Transmitted Infections (STIs)

LEARN MORE

Sexually Transmitted Infections (STIs)

  • 1 in 5 people in the US have an STI.9
  • Different STIs can present with similar symptoms but require distinct treatment, creating a challenge for accurate diagnosis and management.10
  • Untreated STIs can lead to serious health concerns for women, including pelvic inflammatory disease, ectopic pregnancy, and infertility.11
LEARN MORE
Universal Screening Woman

Universal Screening

LEARN MORE

Universal Screening

  • Targets all women ages 15-24 regardless of their reported sexual activity.
  • Detects the care opportunities missed by risk-based screening.12
  • Universal screening can reduce STI prevalence, and thus reduce long-term health consequences like infertility, and can lower overall healthcare costs.13
LEARN MORE
Petal square

Stay Up to Date on Guidelines

Crucial to providing the best care for your patients, we’ve curated key resources to inform your testing practices.

CDC
ACOG
USPSTF

VIEW RESOURCES

Let’s Connect

Have a question or need to talk to a Hologic team member? We’re here to help.

Contact Us
References

*A positive HPV screening result may lead to further evaluation with cytology and/or colposcopy.

1. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/cncy.21544. (Study included ThinPrep®, SurePath and Hybrid Capture 2 High-Risk HPV DNA test).

2. Austin et al. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. Am J Clin Patho 2018; 150:385-392

3. Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV and Hybrid Capture 2)

4. Kent HL. Epidemiology of Vaginitis. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1168-76.

5. Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, Markowitz LE. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007 Nov;34(11):864-9.

6. Van Der Pol B. 2010. Diagnosing vaginal infections: It’s time to join the 21st century. Curr346 Infect Dis Rep 12:225-230.

7. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368-1379.

8. Schwebke JR, Taylor SN, Ackerman R, et al. Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study. J Clin Microbiol. 2020 Jan 28;58(2):e01643-19. doi: 10.1128/JCM.01643-19.

9. CDC. Incidence, Prevalence, and Cost Estimates of Sexually Transmitted Infections in the United States. Last reviewed: April 3, 2024. Accessed October 3, 2025. https://www.cdc.gov/sti/php/communication-resources/prevalence-incidence-and-cost-estimates.html

10. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1.

11. U.S. Department of Health and Human Services. Sexually transmitted infections (STIs) pathogens and syndromes. National Institute of Allergy and Infectious Diseases. Last reviewed: April 10, 2024. Accessed October 3, 2025. https://www.niaid.nih.gov/diseases-conditions/sti-pathogens-and-syndromes

12. Tomcho MM, Lou Y, O’Leary SC, et al. Closing the Equity Gap: An Intervention to Improve Chlamydia and Gonorrhea Testing for Adolescents and Young Adults in Primary Care. J Prim Care Community Health. 2022 Jan-Dec;13:21501319221131382. doi: 10.1177/21501319221131382

13. Owusu-Edusei, Kwame Jr et al. Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S. American journal of preventive medicine vol. 51,2 (2016): 216-224. doi:10.1016/j.amepre.2016.01.007